Source: http://www.google.com/patents/US20030125615?dq=6,587,403
Timestamp: 2015-10-13 17:34:28
Document Index: 62298284

Matched Legal Cases: ['art. 15', 'art. 16', 'art. 17', 'art. 18', 'art. 39', 'art. 40', 'art. 41', 'art. 42', 'art. 64', 'art. 65', 'art. 66', 'art. 67']

Patent US20030125615 - Homing of autologous cells to a target zone in tissue using active ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsA method for inducing vascular growth in tissue of a mammal comprises the steps of isolating endothelial progeniter cells or bone marrow derived stem cells from the mammal; delivering a cytokine or chemoattractant to a target zone of the tissue; and reintroducing the isolated endothelial progenitor cells...http://www.google.com/patents/US20030125615?utm_source=gb-gplus-sharePatent US20030125615 - Homing of autologous cells to a target zone in tissue using active therapeutics or substancesAdvanced Patent SearchPublication numberUS20030125615 A1Publication typeApplicationApplication numberUS 10/281,792Publication dateJul 3, 2003Filing dateOct 28, 2002Priority dateFeb 5, 1998Also published asCA2447167A1, EP1415662A1Publication number10281792, 281792, US 2003/0125615 A1, US 2003/125615 A1, US 20030125615 A1, US 20030125615A1, US 2003125615 A1, US 2003125615A1, US-A1-20030125615, US-A1-2003125615, US2003/0125615A1, US2003/125615A1, US20030125615 A1, US20030125615A1, US2003125615 A1, US2003125615A1InventorsYitzhack SchwartzOriginal AssigneeYitzhack SchwartzExport CitationBiBTeX, EndNote, RefManPatent Citations (5), Referenced by (58), Classifications (50), Legal Events (1) External Links: USPTO, USPTO Assignment, EspacenetHoming of autologous cells to a target zone in tissue using active therapeutics or substances
What is claimed is: 1. A method for inducing vascular growth in tissue of a mammal, the method comprising the steps of: (a) isolating endothelial progenitor cells or bone marrow derived stem cells from the mammal; (b) delivering a translocation stimulator to a target zone of the tissue; and (c) reintroducing the isolated endothelial progenitor cells or bone marrow derived stem cells to the mammal for homing the endothelial progenitor cells or bone marrow derived stem cells to the target zone of the tissue for effecting vascular growth at the target zone. 2. The method according to claim 1, further comprising effecting vascular growth by vasculogenesis. 3. The method according to claim 1, further comprising effecting vascular growth by angiogenesis. 4. The method according to claim 1, further comprising effecting vascular growth by arteriogenesis. 5. The method according to claim 1, further comprising isolating endothelial progenitor cells from blood of the mammal. 6. The method according to claim 1, further comprising isolating bone marrow derived stem cells from the bone marrow of the mammal. 7. The method according to claim 1, further comprising culturing and expanding the isolated endothelial progenitor cells or bone marrow derived stem cells in vitro. 8. The method according to claim 7, further comprising genetically engineering endothelial progenitor cells or bone marrow derived stem cells to produce a marker. 9 The method according to claim 7, further comprising genetically engineering endothelial progenitor cells or bone marrow derived stem cells to produce a therapeutic protein. 10 The method according to claim 1, further comprising delivering at least one translocation stimulator from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα, TGFβ, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα, COX-2 and all isoforms and analogs thereof. 11 The method according to claim 1, further comprising delivering the cytokine translocation stimulator to the target zone of the tissue by injection. 12 The method according to claim 11, further comprising using a catheter for the injection of the translocation stimulator. 13 The method according to claim 12, further comprising navigating the catheter to the target zone using a position sensor on the catheter. 14 The method according to claim 12, further comprising injecting the cytokine translocation stimulator into the myocardium of the heart. 15 The method according to claim 12, further comprising injecting the cytokine translocation stimulator into the epidardium of the heart. 16 The method according to claim 12, further comprising injecting the cytokine translocation stimulator within a vessel of the heart. 17 The method according to claim 12, further comprising injecting the cytokine translocation stimulator into a wall of a vessel of the heart. 18 The method according to claim 1, further comprising identifying the target zone by mapping the tissue for viability. 19 The method according to claim 18, further comprising mapping the tissue for viability using a catheter having an electrode. 20 The method according to claim 19, further comprising navigating the catheter using a position sensor on the catheter. 21 The method according to claim 1, further comprising isolating endothelial progenitor cells by a selectable marker. 22 The method according to claim 21, using at least one selectable marker from the group comprising VEGFR-2, VE-Cadherin, CD34, BDNF, E-Selectin or CXCR4. 23 The method according to claim 21, further comprising reintroducing the isolated endothelial progenitor cells by intravenous administration. 24 The method according to claim 21, further comprising reintroducing the isolated endothelial progenitor cells near the target zone of the tissue. 25 The method according to claim 1, further comprising isolating bone marrow derived stem cells by a selectable marker. 26 The method according to claim 25, further comprising using at least one selectable marker from the group comprising C-Kit, P-Glycoprotein, MRD1 or Sca-1. 27 The method according to claim 25, further comprising reintroducing the isolated bone marrow derived stem cells by intravenous administration. 28 The method according to claim 25, further comprising reintroducing the isolated bone marrow derived stem cells near the target zone of the tissue. 29 A method for inducing myogenesis in tissue of a mammal, the method comprising the steps of: (a) isolating endothelial progeniter cells or bone marrow derived stem cells from the mammal: (b) deliverying a translocation stimulator to a target zone of the tissue; and (c) reintroducing the isolated endothelial progenitor cells or bone marrow derived stem cells to the mammal for homing the endothelial progenitor cells or bone marrow derived stem cells to the target zone of the tissue for effecting myogenesis at the target zone. 30. The method according to claim 29, further comprising isolating endothelial progenitor cells from blood of the mammal. 30. The method according to claim 29, further comprising isolating bone marrow derived stem cells from the bone marrow of the mammal. 31. The method according to claim 29, further comprising culturing and expanding the isolated endothelial progenitor cells or bone marrow derived stem cells in vitro. 32. The method according to claim 32, further comprising genetically engineering endothelial progenitor cells or bone marrow derived stem cells to produce a marker. 33. The method according to claim 32, further comprising genetically engineering endothelial progenitor cells or bone marrow derived stem cells to produce a therapeutic protein. 34. The method according to claim 29, further comprising delivering at least one translocation stimulator from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα, TGFβ, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα, COX-2 and all isoforms and analogs thereof. 35. The method according to claim 29, further comprising delivering the translocation stimulator to the target zone of the tissue by injection. 36. The method according to claim 36, further comprising using a catheter for the injection of the translocation stimulator. 37. The method according to claim 37, further comprising navigating the catheter to the target zone using a position sensor on the catheter. 38. The method according to claim 37, further comprising injecting the cytokine translocation stimulator into the myocardium of the heart. 39. The method according to claim 37, further comprising injecting the cytokine translocation stimulator into the epicardium of the heart. 40. The method according to claim 37, further comprising injecting the cytokine translocation stimulator within a vessel of the heart. 41. The method according to claim 37, further comprising injecting the cytokine translocation stimulator into a wall of a vessel of the heart. 42. The method according to claim 29, further comprising identifying the target zone by mapping the tissue for viability. 43. The method according to claim 43, further comprising mapping the tissue for viability using a catheter having an electrode. 44. The method according to claim 44, further comprising navigating the catheter using a position sensor on the catheter. 45. The method according to claim 29, further comprising isolating endothelial progenitor cells by a selectable marker. 46. The method according to claim 46, using at least one selectable marker from the group comprising VEGFR-2, VE-Cadherin, CD34, BDNF, E-Selectin or CXCR4. 47. The method according to claim 46, further comprising reintroducing the isolated endothelial progenitor cells by intravenous administration. 48. The method according to claim 46, further comprising reintroducing the isolated endothelial progenitor cells near the target zone of the tissue. 49. The method according to claim 29, further comprising isolating bone marrow derived stem cells by a selectable marker. 50. The method according to claim 50, further comprising using at least one selectable marker from the group comprising C-Kit, P-Glycoprotein, MRD1 or Sca-1. 51. The method according to claim 50, further comprising reintroducing the isolated bone marrow deived stem cells by intravenous administration. 52. The method according to claim 50, further comprising reintroducing the isolated bone marrow derived stem cells near the target zone of the tissue. 53. A method for remodeling tissue of a mammal, the method comprising the steps of: (a) isolating endothelial progenitor cells or bone marrow derived stem cells from the mammal; (b) delivering a translocation stimulator to a target zone of the tissue; and (c) reintroducing the isolated endothelial progenitor cells or bone marrow derived stem cells to the mammal for homing the endothelial progenitor cells or bone marrow derived stem cells to the target zone of the tissue for effecting remodeling of the tissue at the target zone. 54. The method according to claim 54, further comprising isolating endothelial progenitor cells from blood of the mammal. 55. The method according to claim 54, further comprising isolating bone marrow derived stem cells from the bone marrow of the mammal. 56. The method according to claim 54, further comprising culturing and expanding the isolated endothelial progenitor cells or bone marrow derived stem cells in vitro. 57. The method according to claim 57, further comprising genetically engineering endothelial progenitor cells or bone marrow derived stem cells to produce a marker. 58. The method according to claim 57, further comprising genetically engineering endothelial progenitor cells or bone marrow derived stem cells to produce a therapeutic protein. 59. The method according to claim 54, further comprising delivering at least one translocation stimulator from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα, TGFβ, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα, COX-2 and all isoforms and analogs thereof. 60. The method according to claim 54, further comprising delivering the translocation stimulator to the target zone of the tissue by injection. 61. The method according to claim 61, further comprising using a catheter for the injection of the translocation stimulator. 62. The method according to claim 62, further comprising navigating the catheter to the target zone using a position sensor on the catheter. 63. The method according to claim 62, further comprising injecting the cytokine translocation stimulator into the myocardium of the heart. 64. The method according to claim 62, further comprising injecting the cytokine translocation stimulator into the epicardium of the heart. 65. The method according to claim 62, further comprising injecting the cytokine translocation stimulator within a vessel of the heart. 66. The method according to claim 62, further comprising injecting the cytokine translocation stimulator into a wall of a vessel of the heart. 67. The method according to claim 54, further comprising identifying the target zone by mapping the tissue for viability. 68. The method according to claim 68, further comprising mapping the tissue for viability using a catheter having an electrode. 69. The method according to claim 69, further comprising navigating the catheter using a position s